Compare · LIVN vs OM
LIVN vs OM
Side-by-side comparison of LivaNova PLC (LIVN) and Outset Medical Inc. (OM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LIVN and OM operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- LIVN is the larger of the two at $3.97B, about 46.8x OM ($84.9M).
- OM has been more active in the news (16 items in the past 4 weeks vs 5 for LIVN).
- LIVN has more recent analyst coverage (20 ratings vs 13 for OM).
- Company
- LivaNova PLC
- Outset Medical Inc.
- Price
- $72.31-1.89%
- $4.58-3.38%
- Market cap
- $3.97B
- $84.9M
- 1M return
- -
- +1.10%
- 1Y return
- -
- -78.38%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 5
- 16
- Recent ratings
- 20
- 13
LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Outset Medical Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Latest LIVN
- LivaNova Appoints Anne Liddy as Chief Legal Officer
- SEC Form SD filed by LivaNova PLC
- Director Bianchi Francesco sold $136,350 worth of Ordinary Shares (1,800 units at $75.75), decreasing direct ownership by 20% to 7,228 units (SEC Form 4)
- LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
- LivaNova to Present at Goldman Sachs Global Healthcare Conference in June
- SEC Form IRANNOTICE filed by LivaNova PLC
- SEC Form 10-Q filed by LivaNova PLC
- LivaNova PLC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
- Amendment: SEC Form SCHEDULE 13G/A filed by LivaNova PLC
Latest OM
- Director Hackett Patrick T was granted 10,667 shares, increasing direct ownership by 11% to 105,839 units (SEC Form 4)
- Director Oboyle Kevin C was granted 10,667 shares, increasing direct ownership by 44% to 34,785 units (SEC Form 4)
- Director Prange Karen was granted 10,667 shares, increasing direct ownership by 57% to 29,334 units (SEC Form 4)
- Director Lang Brent D. was granted 10,667 shares, increasing direct ownership by 60% to 28,518 units (SEC Form 4)
- Director Grossman D Keith was granted 10,667 shares, increasing direct ownership by 77% to 24,585 units (SEC Form 4)
- Director Drexler Karen was granted 10,667 shares, increasing direct ownership by 100% to 21,317 units (SEC Form 4)
- Chief Financial Officer Gaeta Renee sold $87,300 worth of shares (17,672 units at $4.94), decreasing direct ownership by 13% to 113,753 units (SEC Form 4) (for withholding tax)
- Outset Medical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Outset Medical Inc. filed SEC Form 8-K: Leadership Update
- SEC Form SD filed by Outset Medical Inc.